Nanobiotechnology Market Forecasts to 2030 – Global Analysis By Type (10-100 Nm and 0-10 Nm), Therapeutic (Orthopedic Therapies, Dental Therapies, Cardiac Therapies, Liposomes and Other Therapeutics), Technology, Application and By Geography

Nanobiotechnology Market Forecasts to 2030 – Global Analysis By Type (10-100 Nm and 0-10 Nm), Therapeutic (Orthopedic Therapies, Dental Therapies, Cardiac Therapies, Liposomes and Other Therapeutics), Technology, Application and By Geography

According to Stratistics MRC, the Global Nanobiotechnology Market is accounted for $112.66 billion in 2023 and is expected to reach $186.91 billion by 2030 growing at a CAGR of 7.5% during the forecast period. The study of biological systems at the nanoscale level, often including molecules and microscopic particles, is known as nanobiotechnology and is a blend of the nanotechnology and biotechnology fields. Other terms that are used simultaneously with nanobiotechnology include nanobiology and bionanotechnology. The production and usage of materials, devices, and systems through the manipulation of matter at scales smaller than 100 nanometers are collectively referred to as ""nanobiotechnology applications. Globally, governments and businesses are investing heavily in nanobiotechnology.

According to Food & Agriculture Organization, the world population is anticipated to surpass 9.7 billion by 2050.

Market Dynamics

Driver

Increased incidence of chronic diseases

A significant growth driver for the nanobiotechnology market is the rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular problems, around the world. Better solutions to problems with conventional therapies for certain illnesses are provided by nanobiotechnology. For instance, focused therapy is made possible by nanoparticle-based drug delivery systems, which also reduce side effects and enhance patient outcomes. The need for creative nanobiotechnology solutions is growing as the burden of chronic diseases increases globally.

Restraint

High development expenses

Nanobiotechnology products require large investments in infrastructure, specialized equipment, staff, and research and development activities in order to be developed and commercialized. However, nanobiotechnology's high development costs might be a deterrent, especially for startups or small and medium-sized businesses (SMEs) with restricted funding sources. To break through this barrier, access to capital and investment possibilities is essential.

Opportunity

Increasing investments in nanobiotechnology

A rise in the quantity of novel, inventive, and promising products undergoing clinical trials will accelerate the development of the global nanobiotechnology market. Businesses and governments around the world are making significant investments in nanobiotechnology. Additionally, many government organizations have increased the amount of money that is invested in the study and advancement of nanobiotechnology. To bring novel products to market, businesses are actively investing in research and development. In the nanobiotechnology sector, these innovative tools give businesses a competitive advantage.

Threat

Toxicity and long term impacts

Nanobiotechnology makes use of materials at the nanoscale, which have special qualities and potential hazards. Because of this, regulatory bodies have been concerned while certifying and releasing nanobiotechnology products for sale. It is anticipated that increased scrutiny and oversight will be required due to safety concerns over the toxicity and long-term impacts of nanomaterials on human health and the environment. Thus, during the course of the forecast period, these factors are anticipated to hinder the expansion of the nanobiotechnology market.

Covid-19 Impact

The COVID-19 epidemic has highlighted the significance of quick and precise diagnosis as well as the creation of efficient medications and vaccinations. With the ability to increase the sensitivity and specificity of diagnostic tests and enhance drug delivery systems, nanobiotechnology is significant in both fields. The focus on healthcare solutions may have accelerated the expansion of the nanobiotechnology industry. Funds and resources may have been transferred by governments and private investors to research and development in COVID-19-related fields. There may have been more funding available for nanobiotechnology companies focusing on virus-related topics.

The pharmaceuticals segment is expected to be the largest during the forecast period

Pharmaceuticals segment is expected to hold largest share over the projection period. In the manufacturing and distribution of pharmaceutical products, nanoscale materials, devices, and procedures are used. Additionally, this area has the potential to transform medication development, delivery, and therapeutic efficacy, enabling more individualized and focused treatments for a range of illnesses.

The orthopedic therapies segment is expected to have the highest CAGR during the forecast period

Due to significant advances in the creation of nanomaterials, drug delivery systems, and diagnostic instruments specifically designed for orthopedic purposes, the orthopedic therapies segment is anticipated to experience profitable growth over the course of the projected period. Additionally, through the use of nanomaterials like nanoparticles and nanocomposites, nanobiotechnology enables targeted drug delivery to injured tissues, improves the bioavailability of treatments, and supports tissue regeneration. The early detection and monitoring of orthopedic disorders are also being improved by nanoscale imaging and diagnostic methods.

Region with largest share

North America is expected to hold largest share over the projection period. A stable regulatory environment created a favorable atmosphere for the development of nanobiotechnology in the region. The FDA and other regulatory bodies in the US collaborated closely with businesses and researchers to guarantee the efficacy and safety of nanotech products. Additionally, industry collaboration and robust government support are key factors in the regional market's success.

Region with highest CAGR

Due to favorable growth prospects for the pharmaceutical and biotechnology industries brought on by successful clinical trials and eventual Food and Drug Administration (FDA) certification, Europe is expected to have the highest growth. The main drivers of regional market expansion are the increasing demand for technologically advanced products and well-developed R&D facilities. Other aspects that are anticipated to contribute to regional market expansion include the expanding biotechnology sector, government investments and efforts, cancer research and targeted medicines, agriculture and environmental applications, and nanotechnology in electronics and materials.

Key players in the market

Some of the key players in Nanobiotechnology market include Abbott Laboratories, Advanced Nano Products Co., Ltd, Altair Nanotechnologies Inc, Biosensors International Group, Ltd, Bruker Corporation, Calando Pharmaceuticals, Celgene Corporation, Dendritic Nanotechnologies, Elan Pharmaceuticals, eSpin Technologies, Inc, Flamel Technologies, Imina Technologies SA, Johnson & Johnson, Nano Bridging Molecules SA, Novartis AG, Thermo Fisher Scientific Inc and XanTecbioanalytics GmbH.

Key Developments

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes.

Types Covered
• 10-100 Nm
• 0-10 Nm

Therapeutics Covered
• Orthopedic Therapies
• Dental Therapies
• Cardiac Therapies
• Liposomes
• Other Therapeutics

Technologies Covered
• Nanoparticles
• Nanoshells
• Nanotubes
• Other Technologies

Applications Covered
• Genomics
• Drug Delivery
• Proteomics
• Pharmaceuticals
• Food and Agriculture
• Medical Devices
• Medical Research
• Other Applications

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements